Glyde Bio

Glyde Bio was a private biotechnology company based in Cambridge, Massachusetts, focused on cancer immunotherapy against the cancer glycome. The company sought to develop immunotherapies targeting tumor-associated carbohydrate antigens and other glycan-derived neoantigens that are aberrantly expressed on cancer cells. Public descriptions indicate work spanning immunogenic compositions and antibody-based approaches directed at glycoepitopes such as Tn, sialyl-Tn, and Thomsen-Friedenreich-related targets. Glyde Bio appears to have remained at a preclinical stage, with no disclosed clinical pipeline, funding rounds, or marketed products. Multiple business databases list the company as closed as of 2026.